BioVenture eLab Secures $1.5 million State Grant to Broaden Weill Cornell Entrepreneurial Ecosystem
July 10, 2026
Weill Cornell Medicine has received a four-year, $1.5 million grant from New York’s Empire State Development to increase resources available through BioVenture eLab, the institution’s hub for biomedical entrepreneurship.
Gene Therapy Shows Promise for Life-Threatening Inherited Heart Disease
June 17, 2026
A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers. The treatment may also reduce heart damage, although further investigation is needed.
Researchers-turned-inventors Recognized at Bearers of Innovation Celebration
June 16, 2026
On May 20, Cornell’s Center for Technology Licensing (CTL) brought together inventors from across colleges and campuses in Ithaca and at Weill Cornell Medicine in New York City for Bearers of Innovation: A One Cornell Celebration. The event recognized 82 lead inventors who submitted their first invention disclosure to CTL in fiscal year 2024 or fiscal year 2025, and 306 inventors whose technologies were licensed or optioned during that same period.
Innovators Pitch Cell Therapies and AI Tools at Biomedical Innovation Challenge
June 10, 2026
The eighth cohort of the Biomedical Innovation Challenge showcased its innovations and development plans during a lightning round of pitches and judges’ questions on June 4 in the Belfer Research Building.
A Breakthrough Single-Cell Method for Mapping DNA-Protein Interactions
June 4, 2026
A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center. With key advantages over methods currently in use, the technology is expected to be a powerful addition to biologists’ toolkit for studying cells in health and disease.
BioInnovate Conference Showcases Path from Innovation to Scale Through a Growing Ecosystem
May 7, 2026
Over 200 scientists, startup founders and partners in government and industry gathered at Uris Auditorium on April 23 for the 2026 BioInnovate Conference. The event, hosted by BioVenture eLab, part of Weill Cornell Medicine Enterprise Innovation, celebrates the growing ecosystem that turns scientific discovery into scalable healthcare solutions. Speakers and panelists discussed topics ranging from AI in clinical trials to reshoring domestic drug discovery and manufacturing.
Students Design AI-Powered Health Solutions at Cornell Health Hackathon
March 19, 2026
More than 100 students from across Cornell campuses and 17 other universities gathered in New York City March 6–8 for the Cornell Health AI Hackathon. Organized by Entrepreneurship at Cornell with partners including Weill Cornell Medicine’s Englander Institute for Precision Medicine and the Clinical and Translational Science Center, along with Cornell Tech, the event brought together interdisciplinary teams from medicine, engineering, computer science and business.
Moving Beyond Proof-of-Concept: Weill Cornell Technologies Showcased to Investors at Ignite Connect 2026
February 27, 2026
On Jan. 29, Cornell University’s Center for Technology Licensing (CTL) hosted its third annual Ignite Connect virtual partnering forum. The event brought together sixteen teams of Cornell presenters and more than 100 investors and corporate partners to offer pre-seed and seed-stage engagement. Among the presenters are six Weill Cornell innovators and founders whose startups were built on foundational Weill Cornell technology.
Early-career Scientists and Clinicians Sharpen Entrepreneurial Skills in BioVenture eLab Program
December 17, 2025
From light-activated pain relief to next-generation cancer immunotherapies, early-career scientists and clinicians at Weill Cornell Medicine showcased bold ideas for translating lab discoveries into real-world treatments.
